Full-Life Technologies Ltd. announced Sept. 29 the completion of a $77 million financing, comprising $50 million in series C equity and $27 million in debt financing, which will be used to advance a portfolio of radiopharmaceuticals and radionuclide-drug conjugates worldwide.
Takeda Pharmaceutical Co. Ltd. is exiting all work in cell therapies and will seek an external partner to advance the company’s research and clinic-ready cell therapy programs, the company said, noting that it is not currently running any clinical trials using cell therapy technology.
Nanyang Biologics Pte. Ltd. has entered a $1.5 billion business combination agreement with RF Acquisition Corp II, a Nasdaq-listed special purpose acquisition company. Singapore-based Nanyang Biologics (NYB) is building a hybrid platform to revolutionize drug discovery by combining machine learning with natural compound libraries, and NYB claims it is developing one of the world’s largest AI-curated collections of bioactive compounds.
Work at Pharmaengine Inc. has led to the identification of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor in adults, marked by high treatment resistance and poor prognosis. OLIG2, a CNS-specific transcription factor essential for neural development, is highly expressed in GBM and contributes to tumor progression and therapy resistance, making it a promising target for novel therapeutic strategies.
Individuals with the inherited disorder Fanconi anemia cannot properly repair damage to their DNA, increasing risk of cancers such as head and neck squamous cell carcinoma (HNSCC).
Beactica Therapeutics AB has held a first scientific advisory meeting with the Swedish Medical Products Agency (MPA) for BEA-17, the company’s first-in-class small-molecule targeted degrader of lysine demethylase 1 (LSD1) and its co-factor CoREST.
A team of U.S. and South Korean researchers have developed an AI model called MSI-SEER that can not only predict microsatellite instability-high (MSI-H) tumors based on tissue slides, but also flag “what it does not know.” “Have you ever asked ChatGPT anything, and the response was, ‘I don’t know?’” Cheong Jae-ho asked during an interview with BioWorld. “Probably not, and that is the problem with AI now.”
Icecure Medical Ltd. reported that the U.S. FDA has granted marketing authorization to Icecure's de novo application for the Prosense cryoablation system for the local treatment of breast cancer in patients 70 years of age or older with biologically low-risk tumors. The authorized indication includes patients that are not suitable for surgery for breast cancer treatment.
RSS
